Tags

Type your tag names separated by a space and hit enter

Viral Vectors for COVID-19 Vaccine Development.
Viruses. 2021 02 19; 13(2)V

Abstract

Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK.

Authors+Show Affiliations

PanTherapeutics, CH1095 Lutry, Switzerland.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33669550

Citation

Lundstrom, Kenneth. "Viral Vectors for COVID-19 Vaccine Development." Viruses, vol. 13, no. 2, 2021.
Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. Viruses. 2021;13(2).
Lundstrom, K. (2021). Viral Vectors for COVID-19 Vaccine Development. Viruses, 13(2). https://doi.org/10.3390/v13020317
Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. Viruses. 2021 02 19;13(2) PubMed PMID: 33669550.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Viral Vectors for COVID-19 Vaccine Development. A1 - Lundstrom,Kenneth, Y1 - 2021/02/19/ PY - 2021/01/27/received PY - 2021/02/11/revised PY - 2021/02/15/accepted PY - 2021/3/6/entrez PY - 2021/3/7/pubmed PY - 2021/3/7/medline KW - COVID-19 KW - SARS-CoV-2 KW - adenovirus KW - approved vaccine KW - clinical trials KW - preclinical immunization KW - vaccines JF - Viruses JO - Viruses VL - 13 IS - 2 N2 - Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/33669550/Viral_Vectors_for_COVID_19_Vaccine_Development_ L2 - https://www.mdpi.com/resolver?pii=v13020317 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.